-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $25

Benzinga·12/08/2025 12:40:07
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $18 to $25.